Merck KGaA CFO on M&A Hiatus, Third-Quarter Earnings

The transcript features an interview with Merck's CFO, Marcus Kunitz, discussing the company's financial performance, particularly the strong results from the Life Sciences division. The CFO addresses the potential for spinning off the division, the strategic focus on maintaining a balanced portfolio, and the impact of M&A activities. The conversation shifts to the healthcare sector, highlighting the decline in Rebif sales and the launch of a new MS drug, Madame Claude. Bavencio's sales performance and future expectations are also discussed. The interview concludes with an analysis of the economic outlook, noting strengths in healthcare and life sciences, but challenges in the automotive market.

What is the main reason Merck decided to raise its full-year forecast?

• New product launches in healthcare

• Improved economic conditions in Germany

• Strong performance in the life sciences division

• Increased sales in the automotive market

What is Merck's current strategy regarding mergers and acquisitions?

• Spinning off the life sciences division

• Aggressively pursuing new acquisitions

• Reducing the number of business divisions

• Focusing on integrating recent acquisitions

How does Merck view the future sales trend of Rebif?

• Sales will continue to decline steadily

• Sales will experience a sharp decline

• Sales will stabilize at current levels

• Sales are expected to increase significantly

What is the expected impact of the global economy on Merck's healthcare and life sciences markets?

• Moderate positive impact

• Complete market collapse

• No expected change

• Significant negative impact

Which market is showing some weaknesses according to Marcus Kunitz?

• Pharmaceuticals

• Life sciences

• Automotive

• Healthcare